EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies

Daniel Reinhorn iD, Mor Moskovitz, William D Tap, Bob T Li

Cancer · 15.03.2025 · 131 (S1)

DOI: 10.1002/cncr.35780 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 02.04.2025. Verfasst von Daniel Reinhorn und 3 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 116 Literaturangaben. Gefördert von: NASA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ERBB2 (HER2) alterations, including mutations, amplifications, and overexpression are emerging therapeutic targets in non–small cell lung cancer (NSCLC). Despite recent advancements, standard first‐line therapy remains chemotherapy with or without immunotherapy. Several therapies targeting HER2 are under development and have been evaluated in clinical trials with inconsistent efficacy, including monoclonal antibodies, tyrosine kinase inhibitors, and antibody–drug conjugates. A major landmark was recently reached when trastuzumab deruxtecan (T‐DXd), an antibody–drug conjugate, became the first Food and Drug Administration (FDA)‐approved therapy for pretreated HER2‐mutant NSCLC, following the promising efficacy demonstrated in the DESTINY‐Lung trials. Furthermore, T‐DXd has shown efficacy across various tumor types harboring HER2 alterations in the DESTINY‐PanTumor trials, leading to its recent pan‐tumor FDA approval for HER2‐positive solid tumors, highlighting the potential of tumor‐agnostic drug development strategies. In this review, the authors describe the different HER2 alterations and their clinical consequences, including their impact on prognosis and response to standard therapies. They provide an up‐to‐date overview of the current treatment landscape and add a comprehensive review of pivotal and ongoing clinical trials of HER2‐targeted therapies, including tumor‐agnostic drug development strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesLung NeoplasmsCarcinoma, Non-Small-Cell LungHumansDrug DevelopmentMolecular Targeted TherapyImmunoconjugatesProtein Kinase InhibitorsClinical Trials as TopicMutationTrastuzumabCamptothecin

Stichwörter der Autor:innen

HER2 amplificationHER2 mutationHER2 overexpressionantibody–drug conjugatenon‐small cell lung cancerpan‐tumortargeted therapytyrosine kinase inhibitors

Substanzen

Erb-b2 Receptor Tyrosine KinasesImmunoconjugatesProtein Kinase InhibitorsTrastuzumabCamptothecinERBB2 protein, humantrastuzumab deruxtecan

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Weill Cornell Medicine, Cornell University, New York, New York, USA.

ORCID-Profile: Daniel Reinhorn

Förderung

  • NASA

Zitieren

APA

Reinhorn, D., Moskovitz, M., Tap, W. D., & Li, B. T. (2025). Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies. Cancer, 131(S1). https://doi.org/10.1002/cncr.35780

Vancouver

Reinhorn D, Moskovitz M, Tap WD, Li BT. Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies. Cancer. 2025;131(S1). doi:10.1002/cncr.35780

BibTeX
@article{Reinhorn2025,
  author = {Reinhorn, Daniel and Moskovitz, Mor and Tap, William D and Li, Bob T},
  title = {Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {S1},
  doi = {10.1002/cncr.35780}
}
Kostenlos starten →